Amgen
American multinational biopharmaceutical company
Follow Amgen on Notably News to receive short updates to your email — rarely!
| March 2025 | Presented data for Tezspire showing best results for treating chronic rhinosinusitis with nasal polyps and announced start of two late-stage trials for MariTide, a weight loss drug. |
| 2024 | Amgen was ranked 151 on the Fortune 500 list of the largest United States corporations by revenue. |
| October 2023 | Amgen completed the acquisition of Horizon Therapeutics. |
| September 2022 | Presented late-stage study data showing cancer pill Lumakras beating chemotherapy, the first approved drug targeting KRAS mutations. |
| August 2022 | Amgen agreed to acquire ChemoCentryx for $3.7 billion in an all-cash deal. |
| January 2022 | Received approvals for sotorasib in NSCLC in Europe and Japan. |
| 2021 | Executed multiple strategic acquisitions including Five Prime Therapeutics, Rodeo Therapeutics Corporation, Teneobio, and Viela Bio Inc, demonstrating continued aggressive expansion in the biotechnology sector. |
| May 2021 | FDA approved Lumakras for treating patients with KRAS-G12C-mutated non-small cell lung cancer. |
| December 2020 | FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation. |
| December 31 2020 | Amgen reported Total CO2e emissions at 243 kilotonnes, representing a 6% reduction from the previous year and a 2.4% year-over-year decrease. |
| November 2020 | Enrolled first patient in a COVID-19 treatment trial and terminated collaboration with Cytokinetics for omecamtiv mecarbil and AMG 594. |
| October 2020 | Announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC. |
| August 2020 | Amgen, Takeda, and AbbVie announced the first patients enrolled in the I-SPY COVID clinical trial, evaluating treatments for severely ill, hospitalized COVID-19 patients. |
| August 24 2020 | Amgen joined the Dow Jones Industrial Average. |
| July 2020 | Amgen granted an additional $3 million to Khan Academy to support educational equity and science learning. |
| March 2020 | Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts. |
| January 2020 | Amgen Foundation and Harvard University launched LabXchange, a free online science education platform. |
| 2019 | Acquired Nuevolution AB and Otezla (apremilast), expanding the company's pharmaceutical offerings. |
| September 2019 | FDA granted fast track designation to sotorasib for treating metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation. |
| June 2019 | FDA approved Kanjinti (trastuzumab-anns). |
| May 2018 | FDA approved Aimovig (erenumab-aooe) for migraine headaches. |
| 2017 | Acquired River Vision Development Corp., adding to Amgen's research and development portfolio. |
| October 2017 | Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons. |
| 2016 | Acquired Raptor Pharmaceutical, continuing the company's strategy of strategic expansions. |
| September 2016 | FDA approved Amjevita (adalimumab). |
| 2015 | Completed multiple acquisitions including Dezima Pharma, Catherex, Vidara Therapeutics International, Hyperion Therapeutics, and Crealta Holdings, further diversifying Amgen's pharmaceutical research and development capabilities. |
| October 2015 | FDA approved Imlygic (talimogene laherparepvec) for local treatment of unresectable melanoma lesions. |
| August 2015 | FDA approved Repatha (evolocumab). |
| December 2014 | Blincyto (blinatumomab) was approved by the FDA. |
| November 2014 | Amgen halted trials of rilotumumab in advanced gastric cancer patients and reported positive results for brodalumab in a Phase III psoriasis trial. Construction was completed on Amgen's next-generation biomanufacturing facility in Singapore. |
| 2013 | Acquired Onyx Pharmaceuticals and spun off NextCODE genetics, marking a significant restructuring of the company's portfolio. |
| 2013 | Amgen opened an affiliate in China. |
| October 2013 | Amgen acquired Onyx Pharmaceuticals, developer of Kyprolis (carfilzomib). |
| June 2013 | Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding its presence in Turkey and nearby areas. |
| May 2013 | Kevin Sharer retired, and Robert Bradway became CEO of Amgen. |
| 2012 | Executed multiple strategic acquisitions including Micromet Inc, Mustafa Nevzat İlaç, KAI Pharmaceuticals, and deCODE genetics, demonstrating significant expansion in the pharmaceutical and genetic research domains. |
| May 2012 | Robert A. Bradway became Amgen's president and chief executive officer following Sharer's retirement. |
| May 2011 | Amgen acquired BioVex, developer of Imlygic (talimogene laherparepvec). |
| March 2011 | Amgen acquired a manufacturing facility near Dublin, Ireland. |
| November 2010 | FDA approved Xgeva for preventing bone metastasis complications in patients with solid tumors. |
| June 6 2010 | Amgen received FDA approval for Prolia, a protein drug treating post-menopausal osteoporosis, which reduced vertebral fractures by 61% and hip fracture risk by 40%. |
This contents of the box above is based on material from the Wikipedia article Amgen, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.